Medico Remedies Ltd Upgraded to Hold on Improved Valuation and Financial Trends

Quality Assessment: Solid Financial Performance and Operational Efficiency

Medico Remedies has exhibited commendable financial resilience, particularly in the recent quarter Q1 FY26-27. The company reported net sales of ₹126.21 crores over the latest six months, marking a robust growth rate of 58.65%. Profit after tax (PAT) also rose significantly by 36.04% to ₹8.38 crores in the same period. This consistent positive performance is underscored by six consecutive quarters of profit growth, signalling operational stability.

Management efficiency remains a strong point, with a return on capital employed (ROCE) of 15.85% and return on equity (ROE) at 20.67%. These figures indicate effective utilisation of capital and shareholder funds, respectively. Additionally, the company maintains a low debt-to-EBITDA ratio of 0.82 times, reflecting a healthy ability to service debt and a conservative capital structure. Such financial discipline supports the quality rating, which remains steady and contributes positively to the overall upgrade.

Valuation: From Fair to Attractive Amid Peer Comparison

One of the primary drivers behind the rating upgrade is the improvement in valuation metrics. Medico Remedies’ valuation grade has been raised from fair to attractive, reflecting its current market price relative to earnings and enterprise value multiples. The stock trades at a price-to-earnings (PE) ratio of 25.47, which is notably lower than several peers such as Ind-Swift Laboratories (PE 48.42) and Fredun Pharma (PE 56.52). The company’s enterprise value to EBITDA (EV/EBITDA) ratio stands at 20.73, also below many competitors, indicating a relative discount.

Moreover, the price-to-book value ratio is 5.27, and the enterprise value to capital employed is a modest 4.67, further supporting the attractive valuation thesis. The PEG ratio of 0.75 suggests that the stock is undervalued relative to its earnings growth potential, which has been strong at 33.8% over the past year. This valuation improvement is a key factor in the upgrade, signalling that the stock offers better risk-reward prospects compared to its historical pricing and sector peers.

Financial Trend: Strong Growth Amid Mixed Returns

Despite a challenging broader market environment, Medico Remedies has demonstrated encouraging financial trends. The company’s operating profit has grown at an annualised rate of 36.46%, reflecting robust underlying business momentum. Over the past year, the stock has delivered a total return of 5.93%, outperforming the Sensex which declined by 4.10% in the same period. However, longer-term returns have been less favourable, with a three-year stock return of -47.87% compared to the Sensex’s 19.40% gain.

Year-to-date, the stock has underperformed the benchmark, declining 16.57% against the Sensex’s 9.09% fall. This divergence highlights some volatility and sector-specific headwinds. Nonetheless, the company’s consistent profit growth and improving margins provide a solid foundation for future financial performance. The positive quarterly results and strong management efficiency underpin the financial trend rating, which supports the Hold recommendation.

Technical Analysis: Transitioning to a Bearish Outlook

The technical landscape for Medico Remedies has shifted, influencing the overall rating adjustment. The technical grade has changed from mildly bearish to bearish, reflecting weakening momentum in price action. Key indicators present a mixed picture: the weekly MACD remains mildly bullish, but the monthly MACD is bearish. The Relative Strength Index (RSI) is bearish on a weekly basis, with no clear signal monthly.

Bollinger Bands indicate bearish trends on both weekly and monthly charts, while moving averages on the daily timeframe are mildly bearish. The Know Sure Thing (KST) oscillator confirms bearish momentum on weekly and monthly scales. Dow Theory analysis shows no clear trend weekly and a mildly bearish stance monthly. On-balance volume (OBV) is mildly bearish weekly but mildly bullish monthly, suggesting some accumulation despite price weakness.

Price action remains subdued, with the current stock price at ₹42.18, slightly up 1.37% on the day from a previous close of ₹41.61. The 52-week high stands at ₹56.99, while the low is ₹31.00, indicating a wide trading range. Short-term technical weakness tempers enthusiasm, justifying a Hold rating rather than a more bullish stance.

Contextualising Medico Remedies’ Position in the Pharmaceuticals Sector

Medico Remedies operates within the Pharmaceuticals & Biotechnology sector, a space characterised by rapid innovation and regulatory complexity. Compared to its peers, the company’s valuation metrics are more attractive, especially when benchmarked against industry heavyweights such as Ind-Swift Laboratories and Fredun Pharma, which trade at significantly higher multiples. This relative undervaluation, combined with solid financial metrics, makes Medico Remedies a compelling candidate for investors seeking exposure to mid-sized pharmaceutical firms with growth potential.

However, the company’s micro-cap status and recent technical weakness suggest that investors should approach with measured expectations. The stock’s recent one-month return of 10.42% outpaces the Sensex’s 1.86%, signalling short-term momentum, yet the year-to-date and three-year returns highlight volatility and risk. The majority shareholding by promoters provides stability but also concentrates control, which investors should factor into their risk assessment.

Conclusion: Hold Rating Reflects Balanced Outlook

The upgrade of Medico Remedies Ltd’s investment rating from Sell to Hold reflects a balanced reassessment of its fundamentals and market positioning. The company’s improved valuation grade to attractive, underpinned by reasonable PE and EV/EBITDA multiples and a favourable PEG ratio, is a key positive. Strong financial trends, including robust sales and profit growth, high ROCE, and prudent debt management, further support this view.

Conversely, the technical indicators signal caution, with a shift to bearish momentum across multiple timeframes. The stock’s mixed performance relative to the Sensex over various periods also suggests that while the company is stabilising, it has yet to demonstrate sustained outperformance. As such, the Hold rating is appropriate, signalling that investors should monitor developments closely while recognising the stock’s improving fundamentals.

For investors seeking exposure to the Pharmaceuticals & Biotechnology sector, Medico Remedies offers an attractive valuation entry point with solid financial credentials, but the technical caution advises a measured approach.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →